AbbVie Inc. (ABBV): Price and Financial Metrics

AbbVie Inc. (ABBV): $139.90

1.19 (+0.86%)

POWR Rating

Component Grades














  • Quality is the dimension where ABBV ranks best; there it ranks ahead of 97.75% of US stocks.
  • ABBV's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • ABBV's current lowest rank is in the Momentum metric (where it is better than 17.51% of US stocks).

ABBV Stock Summary

  • ABBVIE INC's market capitalization of $243,272,396,747 is ahead of 99.51% of US-listed equities.
  • ABBVIE INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 87.9% of US listed stocks.
  • ABBV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 90.64% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ABBVIE INC are NVO, BABA, TMO, DHR, and PFE.
  • Visit ABBV's SEC page to see the company's official filings. To visit the company's web site, go to

ABBV Valuation Summary

  • In comparison to the median Healthcare stock, ABBV's price/sales ratio is 95.45% higher, now standing at 4.3.
  • Over the past 118 months, ABBV's price/earnings ratio has gone up 3.2.

Below are key valuation metrics over time for ABBV.

Stock Date P/S P/B P/E EV/EBIT
ABBV 2022-09-01 4.3 16.7 19.4 19.0
ABBV 2022-08-31 4.1 16.2 18.8 18.5
ABBV 2022-08-30 4.2 16.4 19.0 18.7
ABBV 2022-08-29 4.2 16.4 19.0 18.7
ABBV 2022-08-26 4.2 16.5 19.1 18.8
ABBV 2022-08-25 4.3 16.8 19.5 19.1

ABBV Growth Metrics

    The 3 year price growth rate now stands at 94.17%.
  • Its 3 year revenue growth rate is now at 73.75%.
  • The 4 year net cashflow from operations growth rate now stands at 89.23%.
ABBV's revenue has moved up $32,107,000,000 over the prior 70 months.

The table below shows ABBV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 57,349 22,923 12,637
2022-03-31 56,725 22,808 12,479
2021-12-31 56,197 22,777 11,542
2021-09-30 55,169 22,556 7,534
2021-06-30 53,729 20,451 6,663
2021-03-31 50,195 18,650 5,159

ABBV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABBV has a Quality Grade of B, ranking ahead of 80.75% of graded US stocks.
  • ABBV's asset turnover comes in at 0.369 -- ranking 131st of 682 Pharmaceutical Products stocks.
  • PLXP, HSTO, and ADMP are the stocks whose asset turnover ratios are most correlated with ABBV.

The table below shows ABBV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.369 0.677 0.119
2021-06-30 0.359 0.656 0.102
2021-03-31 0.335 0.648 0.078
2020-12-31 0.339 0.664 0.070
2020-09-30 0.339 0.687 0.131
2020-06-30 0.372 0.736 0.147

ABBV Stock Price Chart Interactive Chart >

Price chart for ABBV

ABBV Price/Volume Stats

Current price $139.90 52-week high $175.91
Prev. close $138.71 52-week low $105.56
Day low $138.65 Volume 675,301
Day high $139.98 Avg. volume 6,883,848
50-day MA $144.53 Dividend yield 4.07%
200-day MA $144.57 Market Cap 247.36B

AbbVie Inc. (ABBV) Company Bio

Abbvie develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease, hepatitis C, human immunodeficiency virus, endometriosis, thyroid disease, Parkinson's disease, complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. The company was founded in 2012 and is based in North Chicago, Illinois.

ABBV Latest News Stream

Event/Time News Detail
Loading, please wait...

ABBV Latest Social Stream

Loading social stream, please wait...

View Full ABBV Social Stream

Latest ABBV News From Around the Web

Below are the latest news stories about ABBVIE INC that investors may wish to consider to help them evaluate ABBV as an investment opportunity.

3 Great Dividend Stocks to Buy in September

Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ). Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie boasts practically all the characteristics of an outstanding dividend stock, including a stable business with increasing revenue and earnings, solid growth avenues, a juicy yield, a conservative payout ratio, and of course, an impressive history of dividend hikes.

Yahoo | September 3, 2022

5 NYSE Stocks To Watch And Buy: Here Are Fundamental And Technical Reasons Why

There's no better time to build a strong watchlist of great companies than during a serious market correction. In 2022, the NYSE's composite index continues to outperform its Nasdaq sibling. Since the November 2021 peak in the market, the NYSE composite has fallen as much as 20% from its 17,442 peak.

Yahoo | September 2, 2022

3 Dividend Stocks to Buy in September for Passive Income Generation

Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. Here's how they could provide ever-increasing dividend payments to your brokerage account. Shares of Abbott Laboratories (NYSE: ABT) have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests.

Yahoo | September 1, 2022

Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.

Yahoo | August 31, 2022

SkinMedica® Launches Firm & Tone Lotion for Body

Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica® Firm & Tone Lotion for Body, the first product from the professional-grade skincare line formulated to prevent and address visible signs of body skin aging for a toned look.1 It is clinically proven to diminish the look of crepey skin, address uneven skin texture, improve the appearance of body skin firmness and tone, and improve the look of sagging skin.1

Yahoo | August 31, 2022

Read More 'ABBV' Stories Here

ABBV Price Returns

1-mo -0.25%
3-mo -1.39%
6-mo -4.46%
1-year 31.96%
3-year 142.06%
5-year 106.12%
YTD 6.27%
2021 32.43%
2020 27.72%
2019 1.47%
2018 -0.96%
2017 60.08%

ABBV Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABBV Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6777 seconds.